Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed metastatic lung adenocarcinoma (recurrent or de novo) harboring sensitizing EGFR mutations (L858R, exon 19 deletion, G719A, L861Q, S768I, exon 19 insertions) with oligometastatic disease (≤5 discrete lesions of disease irrespective of location, inclusive of the primary lesion):~  * all sites of disease must be amenable to definitive treatment with a local therapy (surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy) as determined by surgery, interventional radiology and radiation oncology~ * all intrathoracic lymph nodes (including hilar, mediastinal, and supraclavicular nodal disease) are considered 1 discrete lesion.~* No brain metastasis is allowed.~* Patients already started on erlotinib are eligible as long as their sites of disease are determined to be eligible for definitive local therapy by consensus of the principal investigators within 12 weeks of the patient first taking erlotinib.~* Lung adenocarcinoma histology confirmed~* Karnofsky Performance Status ≥ 70%~* Adequate bone marrow, liver and renal function, as specified below:~  * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L~ * Hemoglobin ≥ 8 g/dL~ * Platelets ≥ 100 x 109/L~ * Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)~ * AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present~ * Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.~* For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment~* Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter~Exclusion Criteria:~* Treatment with TKI prior to developing metastatic disease~* Malignant pleural effusion or pleural disease~* Leptomeningeal disease or brain metastasis.~* Any site of disease that is not amenable to definitively local therapy including surgery or radiation therapy~* Women who are breastfeeding or pregnant~* Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment.~* Any medical co-morbidities that would preclude surgery or radiation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- TKI without SBRT (Type: ACTIVE_COMPARATOR): Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.~The oligometastatic disease will not receive SBRT
- TKI with SBRT (Type: EXPERIMENTAL): experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions.

Based on this trial design, predict the completion outcome and termination type (if applicable).